Bioactivity of Peptides Released During Lactic Fermentation of Amaranth Proteins with Potential Cardiovascular Protective Effect: An In Vitro Study.

Fermentation has shown to be an effective technique in bioactive peptides release. That is why in this study antihypertensive, antithrombotic, and antioxidant activity was evaluated during amaranth proteins fermentation with Lactobacillus casei Shirota and Streptococcus thermophilus 54102 in mono and combined culture. During fermentation an increase of free amine groups was observed, and no statistical differences among monocultures were shown, getting higher concentration in combined culture. This was related to antihypertensive and antioxidant activities, where the highest values were also found in the combined process (45% of angiotensin-converting enzyme inhibition, and 168 µmol Trolox equivalents per liter [TE/L] for 2,2-diphenyl-1-picrylhydrazyl, 268 µmol TE/L for 2,2'-azino-bis 3-ethylbenzothiazoline-6-sulfonic acid, and 381 µmol Fe2E/L for ferric reducing ability of plasma). On the contrary, antithrombotic activity was not related to free amine groups during fermentation, having the highest bioactivity in different moments in each experiment. L. casei Shirota and S. thermophilus 54102 are strains that are able to release bioactive peptides from amaranth protein, although amaranth is not a common matrix for the development of lactic acid bacteria. In addition, in this study it was observed for the first time that lactic acid strains are able to release bioactive peptides from amaranth protein. In addition, this methodology could be part for the development of fermented beverages, different from fermented milk, to diversify matrix to obtain a novel functional food.

Primera guía clínica basada en la evidencia médica para la suplementación con probióticos en la farmacia comunitaria española / First clinical guide based on medical evidence for probiotic supplementation in Spanish community pharmacies

Se ha elaborado la primera guía clínica española que permitirá a los farmacéuticos comunitarios y demás profesionales de la salud seleccionar, para cada indicación específica, el producto con probióticos adecuado, la dosis y la vía de administración. Con ello se pretende lograr que la práctica diaria de indicación farmacéutica de los suplementos probióticos esté basada en las mejores evidencias científicas disponibles

We have developed the first Spanish clinical guide that will allow the community pharmacists and other health care professionals easily select the right product with probiotics, dosage and format for each specific indication. With the proposed guide, it is our goal that the daily pharmaceutical practice of probiotics supplementation in community pharmacy is based on the best scientific evidence available (AU)